Welcome to LookChem.com Sign In|Join Free
  • or
WYE-687 is an ATP-competitive and selective inhibitor of mammalian target of rapamycin (mTOR), a protein that plays a crucial role in cell growth, proliferation, and survival. It has been studied for its potential therapeutic applications in various cancer types.
Used in Oncology:
WYE-687 is used as an inhibitor for mTOR, which is a key protein involved in cell growth and proliferation. It has been shown to be effective in overcoming resistance to mTOR kinase inhibitors (mTorKIs) in patients with renal cell carcinoma or colorectal cancer when used in combination with Ras-Raf-MEK1/2 inhibitors. This combination therapy may enhance the efficacy of treatment and improve patient outcomes.

1062161-90-3

Post Buying Request

1062161-90-3 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1062161-90-3 Usage

Biological Activity

wye-687 is an atp-competitive inhibitor of mtor with ic50 value of 7nm [1].wye-687 is a small-molecule pyrazolopyrimidine inhibitor of mtor1 and mtor2. in the immune-complex kinase assay using his6-akt and his6-s6k as the specific substrates of mtor1 and mtor2, wye-687 prevents mtor from phosphorylating the substrates dose-dependently. besides that, wye-687 is found to highly selective against pi3kα (>100-fold) and pi3kγ (>500-fold) as well as 24 other protein kinases. it is found that wye-687 can suppress cell growth via causing a strong g1 arrest in cell cycle in tumor cell lines including mda361 and hct116. wye-687 also affects the angiogenic factor of cancer cells. it reduces the expression of hif-1α in u87mg, mda361 and lncap cells [1].

references

[1] yu k, toral-barza l, shi c, et al. biochemical, cellular, and in vivo activity of novel atp-competitive and selective inhibitors of the mammalian target of rapamycin. cancer research, 2009, 69(15): 6232-6240.

Check Digit Verification of cas no

The CAS Registry Mumber 1062161-90-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,6,2,1,6 and 1 respectively; the second part has 2 digits, 9 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1062161-90:
(9*1)+(8*0)+(7*6)+(6*2)+(5*1)+(4*6)+(3*1)+(2*9)+(1*0)=113
113 % 10 = 3
So 1062161-90-3 is a valid CAS Registry Number.

1062161-90-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name methyl N-[4-[4-morpholin-4-yl-1-[1-(pyridin-3-ylmethyl)piperidin-4-yl]pyrazolo[3,4-d]pyrimidin-6-yl]phenyl]carbamate

1.2 Other means of identification

Product number -
Other names pyrazolo pyrimidine,9

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1062161-90-3 SDS

1062161-90-3Downstream Products

1062161-90-3Relevant academic research and scientific papers

ATP-competitive inhibitors of the mammalian target of rapamycin: Design and synthesis of highly potent and selective pyrazolopyrimidines

Zask, Arie,Verheijen, Jeroen C.,Curran, Kevin,Kaplan, Joshua,Richard, David J.,Nowak, Pawel,Malwitz, David J.,Brooijmans, Natasja,Bard, Joel,Svenson, Kristine,Lucas, Judy,Toral-Barza, Lourdes,Zhang, Wei-Guo,Hollander, Irwin,Gibbons, James J.,Abraham, Robert T.,Ayral-Kaloustian, Semiramis,Mansour, Tarek S.,Yu, Ker

supporting information; experimental part, p. 5013 - 5016 (2010/03/04)

The mammalian target of rapamycin (mTOR), a central regulator of growth, survival, and metabolism, is a validated target for cancer therapy. Rapamycin and its analogues, allosteric inhibitors of mTOR, only partially inhibit one mTOR protein complex. ATP-competitive, global inhibitors of mTOR that have the potential for enhanced anticancer efficacy are described. Structural features leading to potency and selectivity were identified and refined leading to compounds with in vivo efficacy in tumor xenograft models.

PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS

-

Page/Page column 103, (2008/12/08)

The present invention relates to Pyrazolopyrimidine Analogs, methods of making Pyrazolopyrimidine Analogs, compositions comprising a Pyrazolopyrimidine Analog, and methods for treating mTOR-related disorders comprising administering to a subject in need thereof an effective amount of a Pyrazolopyrimidine Analog. The invention also relates to treating PI3K-related disorders comprising administering to a subject in need thereof an effective amount of a Pyrazolopyrimidine Analog.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1062161-90-3